Document:

EX-10.1

 Exhibit 10.1 

VOTING AND SUPPORT AGREEMENT 

This VOTING AND SUPPORT AGREEMENT, dated as of November 12, 2020 (this “Agreement”) is made and entered into by
and between Urovant Sciences Ltd., an exempted limited company incorporated under the laws of Bermuda (the “Company”), and Sumitovant Biopharma Ltd., an exempted limited company incorporated under the laws of Bermuda
(“Shareholder”). Capitalized terms used but not defined herein have the meanings ascribed to them in the Merger Agreement (as defined below). 

RECITALS 
 WHEREAS,
concurrently with the execution of this Agreement, the Company, Shareholder, Titan Ltd., an exempted limited company incorporated under the laws of Bermuda and a wholly owned Subsidiary of Shareholder (“Merger Sub”) and, solely with
respect to Section 9.13 of the Merger Agreement (as defined below), Sumitomo Dainippon Pharma Co., Ltd., a company organized under the laws of Japan (“Sumitomo”), have entered into that certain Agreement and Plan of Merger (as
it may be amended from time to time, the “Merger Agreement”), pursuant to which, among other things, Merger Sub will be merged with and into the Company (the “Merger”), with the Company continuing as the surviving
company as a wholly owned Subsidiary of Shareholder; 
 WHEREAS, as of the date hereof, Shareholder is the record or beneficial owner of the
number and type of equity interests of the Company (“Shares”) set forth on Schedule A hereto ((as it may be amended pursuant to Section 5 of this Agreement), together with any additional Shares or
other voting securities of the Company which Shareholder owns of record or beneficially as of the date hereof or of which Shareholder acquires after the date hereof record or beneficial ownership, including by purchase, as a result of a share
dividend, share split, recapitalization, combination, reclassification, redesignation or exchange, upon exercise or conversion of any options, warrants or other securities, or otherwise, “Covered Shares”); and 

WHEREAS, as a condition and inducement to the Company’s willingness to enter into the Merger Agreement and to proceed with the
transactions contemplated thereby (the “Transactions”), including the Merger, the Company and Shareholder are entering into this Agreement. 

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements herein contained, and intending to be legally bound
hereby, the Company and Shareholder hereby agree as follows: 

 AGREEMENT 

1.    Agreement to Vote. 

a.    From the date hereof until the earlier of the Termination Date (as defined below) or the Closing, Shareholder
irrevocably and unconditionally agrees that it will at any meeting of the shareholders of the Company (whether annual, special or otherwise and whether or not an adjourned or postponed meeting), however called, or in connection with any written
consent of shareholders of the Company, however proposed: 
 i.    (A) when a meeting is held, appear at such meeting
or otherwise cause the Covered Shares to be counted as present thereat for the purpose of establishing a quorum, and when a written consent is proposed, respond to each request by the Company for written consent and (B) so long as Shareholder
is not prohibited by applicable Law or prohibited by a contractual obligation with the Company, vote or consent, or cause to be voted at such meeting or cause such consent to be granted with respect to, all Covered Shares in favor of (x) the
Merger and the adoption of the Merger Agreement and the Statutory Merger Agreement (each as they may be amended from time to time), including with respect to the Company Shareholder Approval and (y) each of the other Transactions and documents
relating thereto of which approval of the Company’s stockholders is solicited; and 
 ii.    so long as
Shareholder is not prohibited by applicable Law or prohibited by a contractual obligation with the Company, vote or consent, or cause to be voted at such meeting or cause such consent to be granted with respect to, all Covered Shares against any
matter that would reasonably be expected to impede, interfere with, delay, postpone or adversely affect the consummation of the Merger or any of the other Transactions if the Special Committee recommends a vote against such matter. 

b.    Shareholder hereby gives any consents or waivers that are reasonably required for the consummation of the Merger
under the terms of any Contracts between the Company or any of its Affiliates, on the one hand, and Shareholder or any of its Subsidiaries, on the other hand, or pursuant to any rights Shareholder may have under such Contracts. 

2.    No Inconsistent Agreements. Shareholder hereby represents, covenants and agrees that, except as contemplated
by this Agreement, Shareholder (a) has not entered into, and will not enter into at any time prior to the Termination Date, any voting agreement, voting trust or other agreement that directly or indirectly addresses or involves voting with
respect to any Covered Shares and (b) has not granted, and will not grant at any time prior to the Termination Date, a proxy or power of attorney, or enter into any voting trust, with respect to any Covered Share. 

3.    Termination. This Agreement will terminate upon the earliest of (a) the Closing, (b) the date that
the Merger Agreement is validly terminated in accordance with Section 8.01 of the Merger Agreement and (c) an Adverse Recommendation Change (such earliest date, the “Termination Date”); provided, that the provisions set
forth in Sections 9 and 12 through 23 will survive the termination of this Agreement; provided further, that any liability incurred by any party hereto as a result of a breach of a term or condition of this Agreement prior to
the Termination Date will survive the termination of this Agreement, but that, notwithstanding anything to the contrary contained herein, Shareholder will not be liable for any money damages for any breach of this Agreement, other than a breach
resulting from an action or omission intentionally taken (or failed to 

 
be taken) by Shareholder with the knowledge that such action or omission would, or would reasonably be expected to, cause such breach of a representation, warranty, covenant or obligation of
Shareholder contained in this Voting Agreement. 
 4.    Representations and Warranties of Shareholder.
Shareholder hereby represents and warrants to the Company as follows: 
 a.    Schedule A lists all shares and
other equity interests owned of record or beneficially by Shareholder in the Company as of the date hereof. Schedule A lists all options, warrants and other securities convertible into or exercisable or exchangeable for shares and other
equity interests in the Company owned of record or beneficially by Shareholder as of the date hereof. Except as set forth on Schedule A, as of the date hereof, Shareholder does not own of record or beneficially any voting securities or other
equity securities in the Company or any securities convertible into or exercisable or exchangeable for any such voting securities or other equity securities. Shareholder does not own of record any shares that are beneficially owned by a third
Person. 
 b.    Shareholder is the record or beneficial owner of, and has good and valid title to, all Covered Shares
as of the date hereof, free and clear of all liens, pledges, restrictions and other encumbrances (a “Lien”), other than (i) as created by this Agreement, (ii) as created by any applicable securities Laws, (iii) under
the Company Memorandum of Association or Company Bye-Laws, (iv) under that certain Investor Rights Agreement dated as of December 27, 2019 among the Company, Shareholder and Sumitomo(the
“Investor Rights Agreement”), or (v) as would not impair Shareholder’s ability to timely perform its obligations under this Agreement. Shareholder has sole voting power, sole power of disposition and sole power to agree to
all of the matters set forth in this Agreement, in each case with respect to all of such Covered Shares, with no limitations, qualifications or restrictions on such rights. Except as pursuant to the Investor Rights Agreement, such Covered Shares are
not subject to any voting trust agreement or other contract to which Shareholder is a party restricting or otherwise relating to the voting or sale (constructive or otherwise), transfer, pledge, hypothecation, grant, gift, encumbrance, assignment or
other disposal or disposition (collectively, “Transfer”) of such Covered Shares. Shareholder has not appointed or granted any proxy or power of attorney that is still in effect with respect to such Covered Shares, except as
contemplated by this Agreement. 
 c.    Shareholder has full legal power, authority and capacity to execute and deliver
this Agreement and to perform Shareholder’s obligations hereunder. This Agreement has been duly and validly executed and delivered by Shareholder and, assuming due authorization, execution and delivery by the Company, constitutes a legal, valid
and binding obligation of Shareholder, enforceable against Shareholder in accordance with its terms, except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors’
rights generally and by general principles of equity (regardless of whether considered in a proceeding in equity or at law). 

 d.    Except for the applicable requirements of the Exchange Act,
(i) no filing with, and no Permit is necessary on the part of Shareholder for the execution, delivery and performance of this Agreement by Shareholder or the consummation by Shareholder of the transactions contemplated hereby and (ii) none
of the execution, delivery or performance of this Agreement by Shareholder or the consummation by Shareholder of the transactions contemplated hereby or compliance by Shareholder with any of the provisions hereof will (A) result in any breach
or violation of, or constitute a default (or an event which, with notice or lapse of time or both, would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, or result in the creation of a
Lien on any property or asset of Shareholder pursuant to, any contract to which Shareholder is a party or by which Shareholder or any property or asset of Shareholder is bound or affected or (B) violate any Law or Judgment applicable to
Shareholder or any of Shareholder’s properties or assets except, in the case of clause (A) or (B), for breaches, violations or defaults that would not, individually or in the aggregate, materially impair the ability of Shareholder to
perform its obligations hereunder on a timely basis. 
 e.    There is no Action pending against Shareholder or, to the
actual knowledge of Shareholder, any other Person or, to the actual knowledge of Shareholder, threatened against Shareholder that restricts or prohibits (or, if successful, would restrict or prohibit) the exercise by the Company of its rights under
this Agreement or the performance by Shareholder of its obligations under this Agreement on a timely basis. 

f.    Shareholder understands and acknowledges that the Company is entering into the Merger Agreement in reliance upon
Shareholder’s execution and delivery of this Agreement and the representations and warranties and covenants of Shareholder contained herein and would not enter into the Merger Agreement if Shareholder did not enter into this Agreement. 

5.    Certain Covenants of Shareholder. Shareholder hereby covenants and agrees as follows: 

a.    Except as contemplated hereby and until the earliest of the Termination Date or the Closing, Shareholder will not
(i) tender any Covered Shares into any tender or exchange offer, (ii) Transfer or enter into any contract with respect to the Transfer of any of the Covered Shares or beneficial ownership or voting power thereof or therein (including by
operation of Law), (iii) grant any proxies or powers of attorney, deposit any Covered Shares into a voting trust or enter into a voting agreement with respect to any Covered Shares that is inconsistent with this Agreement or (iv) take any
action that would make any representation or warranty of Shareholder contained herein untrue or incorrect in any material respect or have the effect of preventing, delaying, impairing or disabling Shareholder from performing its obligations under
this Agreement in any material respect. Any Transfer in violation of this Section 5(a) will be void. 

b.    In the event that Shareholder acquires record or beneficial ownership of, or the power to vote or direct the voting
of, any additional Shares or other voting 

 
interests with respect to the Company, such Shares or voting interests will, without further action of the parties, be deemed Covered Shares and subject to the provisions of this Agreement, and
the number of Shares held by Shareholder set forth on Schedule A hereto will be deemed amended accordingly and such Shares or voting interests will automatically become subject to the terms of this Agreement. Shareholder will promptly notify
the Company in writing of any such event. 
 c.    Shareholder hereby waives, and agrees not to exercise or assert, if
applicable, any appraisal rights (including, without limitation, under Section 106(6) of the Bermuda Companies Act) in connection with the Merger. 

d.    Subject to the terms and conditions of this Agreement, Shareholder shall use commercially reasonable efforts to
take, or cause to be taken, all actions, and to do, or cause to be done, all things necessary to fulfill Shareholder’s obligations under this Agreement. 

6.    Shareholder Capacity. Notwithstanding any provision of this Agreement to the contrary, nothing in this
Agreement will limit or restrict a designee of Shareholder from acting in his or her capacity as a director of the Company or fulfilling the obligations of such office, including by acting or voting in his or her capacity as a director of the
Company, in such designee’s sole discretion on any matter, including causing the Company to exercise rights under the Merger Agreement (in accordance with the terms thereof), and no such actions or omissions will be deemed a breach of this
Agreement (it being understood that this Agreement will apply to Shareholder solely in Shareholder’s capacity as a shareholder of the Company). 

7.    No Ownership Interest. Nothing contained in this Agreement will be deemed to vest in the Company any direct
or indirect ownership or incidence of ownership of or with respect to any Covered Shares. All ownership and economic benefits of and relating to the Covered Shares will remain vested in and belong to Shareholder, and, except as otherwise provided
herein, the Company will have no authority to direct Shareholder in the voting or disposition of any Covered Shares. 

8.    Disclosure. Each party hereto hereby authorizes the Company to publish and disclose in any announcement or
disclosure Shareholder’s identity and ownership of the Covered Shares and the nature of Shareholder’s obligations under this Agreement, and to disclose a copy of this Agreement, in each case, to the extent required by applicable Law. 

9.    Expenses. Except as otherwise expressly provided herein, Shareholder, on the one hand, and the Company, on
the other hand, will pay all of their own expenses (including attorneys’ and accountants’ fees and expenses) in connection with the negotiation of this Agreement, the performance of their respective obligations hereunder and the
consummation of the transactions contemplated by this Agreement. 

 10.    Further Assurances. From time to time, at the request of
the other parties hereto and without further consideration, each party hereto will take such further action as may reasonably be deemed by any of the other parties hereto to be necessary or desirable to consummate and make effective the transactions
contemplated by this Agreement. 
 11.    Amendment or Supplement. This Agreement may not be amended, modified or
supplemented in any manner, whether by course of conduct or otherwise, except by an instrument in writing specifically designated as an amendment hereto, signed on behalf of each party hereto. 

12.    Extension; Waiver. At any time prior to the Effective Time, the Parties may (a) extend the time for the
performance of any of the obligations or other acts of the other parties; (b) waive any inaccuracies in the representations and warranties contained in this Agreement or in any document delivered pursuant to this Agreement; (c) waive
compliance with any covenants and agreements contained in this Agreement; or (d) waive the satisfaction of any of the conditions contained in this Agreement. No extension or waiver by the Company will require the approval of the Company’s
shareholders unless such approval is required by Law but will be at the direction of and approved by the Special Committee. Any agreement on the part of a party to any such extension or waiver will be valid only if set forth in an instrument in
writing signed on behalf of such party. No failure or delay by any party in exercising any right, power, or privilege hereunder will operate as a waiver thereof nor will any single or partial exercise thereof preclude any other or further exercise
thereof or the exercise of any other right, power, or privilege. The rights and remedies herein provided will be cumulative and not exclusive of any rights or remedies provided by Law. 

13.    Interpretation. 

a.    When a reference is made in this Agreement to an Article, a Section, a Schedule or an Exhibit, such reference will
be to an Article, a Section, a Schedule or an Exhibit of or to this Agreement unless otherwise indicated. All Exhibits and Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth
herein. The headings contained in this Agreement are for reference purposes only and will not affect in any way the meaning or interpretation of this Agreement. Any capitalized term used in any Exhibit or Schedule but not otherwise defined therein
has the meaning assigned to such term in this Agreement. Whenever the words “include,” “includes” or “including” are used in this Agreement, they will be deemed to be followed by the words “without
limitation.” The words “hereof,” “hereto,” “hereby,” “herein” and “hereunder” and words of similar import when used in this Agreement will refer to this Agreement as a whole and not to any
particular provision of this Agreement. The term “or” is not exclusive. The word “extent” in the phrase “to the extent” will mean the degree to which a subject or other thing extends, and such phrase will not mean
simply “if.” The following general rules apply: the singular number will include the plural, and vice versa; the masculine gender will include the feminine and neuter genders; the feminine gender will include the masculine and neuter
genders; and the neuter gender 

 
will include the masculine and feminine genders. Any Law defined or referred to herein or in any agreement or instrument that is referred to herein will include any modification, amendment or re-enactment thereof, and any Law substituted therefore, in each case as of the time of inquiry, representation, or covenant and all rules, regulations and statutory instruments issued or related to such Law. Any
reference to a Governmental Entity will be also deemed to refer to any successor thereto unless the context requires otherwise. A reference to any agreement (including this Agreement), or Contract is, unless otherwise specified, to the agreement,
Contract as amended, modified, supplemented or replaced at the time of inquiry, representation or covenant. Neither the specification of any dollar amount in this Agreement nor the inclusion of any specific item in the Schedules or Exhibits is
intended to imply that such amounts or higher or lower amounts, or the items so included or other items, are or are not material, and no Party will use the fact of setting of such amounts or the fact of the inclusion of such item in the Schedules or
Exhibits in any dispute or controversy between or among the Parties as to whether any obligation, item or matter is or is not material for purposes of this Agreement. No prior draft of this Agreement nor any course of performance or course of
dealing will be used in the interpretation or construction of this Agreement. Although the same or similar subject matters may be addressed in different provisions of this Agreement, the Parties intend that, except as reasonably apparent on the face
of the Agreement or as expressly provided in this Agreement, each such provision will be read separately, be given independent significance and not be construed as limiting any other provision of this Agreement (whether or not more general or more
specific in scope, substance or content). References herein to a Person are also to its successors and permitted assigns. Unless otherwise specifically indicated, all references to “$” will be deemed references to the lawful money of the
United States of America. 
 b.    Each party represents and agrees with each other that it has been represented by or
had the opportunity to be represented by, independent counsel of its own choosing, and that it has had the full right and opportunity to consult with its respective attorney(s), that to the extent, if any, that it desired, it availed itself of this
right and opportunity, that it or its authorized officers (as the case may be) have carefully read and fully understand this Agreement in its entirety and have had it fully explained to them by such party’s respective counsel, and that it or
its authorized officer (as the case may be) is competent to execute this Agreement and has executed this Agreement free from coercion, duress or undue influence. The parties have participated jointly in the negotiation and drafting of this Agreement
in connection with the Transactions, with the opportunity to seek advice as to their legal rights from such counsel. In the event an ambiguity or question of intent or interpretation arises, this Agreement is to be construed as jointly drafted by
the parties hereto and no presumption or burden of proof is to arise favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement or by reason of the extent to which any such provision is inconsistent with any
prior draft hereof. 

 14.    Notices. All notices, requests, claims, demands and other
communications under this Agreement will be in writing (including email, so long as a receipt of such email is requested and received) and will be given to the addresses set forth below, or pursuant to such other instructions as may be designated in
writing by the Party to receive such notice: 
 if to the Company, to: 

Urovant Sciences Ltd. 
 5281
California Ave., Suite #100 
 Irvine, CA 92671 

Email:          bryan.smith@urovant.com 

Attention:    General Counsel 

with a copy (which will not constitute notice) to: 

O’Melveny & Myers LLP 

610 Newport Center Drive, 17th Floor 

Newport Beach, California 92660 

Facsimile:    (949) 823-6994 

Email:          mpeterson@omm.com 

Attention:    Mark D. Peterson 

if to Shareholder, to: 
 Sumitovant Biopharma
Ltd. 
 11-12 St. James’s Square, Suite 1,
3rd Floor 
 London, United Kingdom SW1Y 4LB 

Email:          marianne.romeo@roivant.com 

Attention:    Marianne L. Romeo, Head, Global Transactions & Risk Management 

and to: 
 Sumitovant Biopharma, Inc. 

151 W. 42nd Street, 15th Floor 

New York, NY 10036 

Email:          tara.soni@sumitovant.com 

Attention:    Tara Soni, Head of Legal and Compliance 

and to: 
 Sumitomo Dainippon Pharma Co., Ltd.

 6-8, Doshomachi 2-Chome,
Chuo-ku 
 Osaka, Japan 541-0045 

Facsimile:    +81-3-5159-3004 

Email:          tsutomu-nakagawa@ds-pharma.co.jp 

Attention:    Tsutomu Nakagawa, Senior Director, Global Corporate Strategy 

 with a copy (which will not constitute notice) to: 

Jones Day 
 3161 Michelson Drive

 Irvine, California 91612 

Facsimile:    (949) 553-7539 

Email:          jonnbeeson@jonesday.com 

Attention:    Jonn R. Beeson 

All such notices, requests and other communications will be deemed received on the date of receipt by the recipient thereof if received prior to 5:00 p.m. on
a Business Day in the place of receipt. Otherwise, any such notice, request, or communication will be deemed to have been received on the next succeeding Business Day in the place of receipt. 

15.    Entire Agreement. This Agreement and the Merger Agreement (including the Exhibits, Company Disclosure
Letter) constitute the entire agreement, and supersede all prior written agreements, arrangements, communications and understandings and all prior and contemporaneous oral agreements, arrangements, communications and understandings between the
parties with respect to the subject matter hereof. 
 16.    No Third-Party Beneficiaries. Nothing in this
Agreement, express or implied, is intended to or will confer upon any Person other than the parties and their respective successors and permitted assigns any legal or equitable right, benefit, claim or remedy of any nature under or by reason of this
Agreement. 
 17.    Non-Recourse. This Agreement may only be enforced
against, and any claim or cause of action based upon, arising out of, or related to this Agreement may only be brought against, the Persons that are expressly named as parties to this Agreement. Except to the extent named as a party to this
Agreement, and then only to the extent of the specific obligations of such parties set forth in this Agreement, no past, present or future shareholder, member, partner, manager, director, officer, employee, Affiliate, agent or representative of any
party to this Agreement will have any Liability (whether in contract, tort, equity or otherwise) for any of the representations, warranties, covenants, agreements or other obligations or Liabilities of any of the parties to this Agreement or for any
claim based upon, arising out of or related to this Agreement. 
 18.    Governing Law. THIS AGREEMENT, INCLUDING
ALL MATTERS OF CONSTRUCTION, VALIDITY AND PERFORMANCE AND ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER IN CONTRACT, TORT, EQUITY OR OTHERWISE) DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OF THE TRANSACTIONS
CONTEMPLATED BY THIS AGREEMENT OR THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT HEREOF, WILL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF DELAWARE, REGARDLESS OF THE LAWS THAT MIGHT OTHERWISE GOVERN UNDER
ANY APPLICABLE PRINCIPLES OF CHOICE OR CONFLICTS OF LAWS OF THE STATE OF DELAWARE, EXCEPT TO THE EXTENT THE PROVISIONS OF THE LAWS OF BERMUDA ARE MANDATORILY APPLICABLE TO THE MERGER. 

 19.    Specific Enforcement; Jurisdiction; Venue. The parties
acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached, and that monetary damages, even if available,
would not be an adequate remedy therefor. It is accordingly agreed that the parties will be entitled to an injunction or injunctions to prevent breaches or threatened breaches of this Agreement and to enforce specifically the performance of the
terms and provisions of this Agreement, including failing to take such actions as are required of them hereunder to consummate the Transactions. It is agreed that the parties are entitled to enforce specifically the performance of terms and
provisions of this Agreement in any court referred to below, without proof of actual damages (and each party hereby waives any requirement for the securing or posting of any bond in connection with such remedy), this being in addition to any other
remedy to which they are entitled at law or in equity. The parties further agree not to assert that a remedy of specific enforcement is unenforceable, invalid, contrary to Law or inequitable for any reason, nor to assert that a remedy of monetary
damages would provide an adequate remedy for any such breach. In addition, each of the parties hereto irrevocably agrees that any Action arising out of or relating to this Agreement brought by (x) Shareholder or any of its Affiliates against
the Company or its Affiliates and (y) by the Company or any of its Subsidiaries against Shareholder or any of its Affiliates, in any such case, will be brought and determined in the Court of Chancery of the State of Delaware; provided, that if
jurisdiction is not then available in the Court of Chancery of the State of Delaware, then any such Action may be brought in any federal court located in the State of Delaware or any other Delaware state court, in each case, except to the extent
that any such proceeding mandatorily must be brought in Bermuda. Each of the parties hereby irrevocably submits to the jurisdiction of the aforesaid courts for itself and with respect to its property, generally and unconditionally, with regard to
any such Action arising out of or relating to this Agreement and the transactions contemplated hereby. Each of the parties agrees not to commence any Action relating thereto except in the courts described above in Delaware, other than Actions in any
court of competent jurisdiction to enforce any judgment, decree or award rendered by any such court in Delaware as described herein. Each of the parties further agrees that notice as provided herein will constitute sufficient service of process and
the parties further waive any argument that such service is insufficient. Each of the parties hereby irrevocably and unconditionally waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any Action arising
out of or relating to this Agreement or the transactions contemplated hereby, (a) any claim that it is not personally subject to the jurisdiction of the courts in Delaware as described herein for any reason, (b) that it or its property is
exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise)
and (c) that (i) the Action in any such court is brought in an inconvenient forum, (ii) the venue of such Action is improper or (iii) this Agreement, or the subject matter hereof, may not be enforced in or by such courts. 

 20.    Assignment; Successors. Neither this Agreement nor any of
the rights, interests or obligations under this Agreement may be assigned or delegated, in whole or in part, by operation of law or otherwise, by either party without the prior written consent of the other party, and any such assignment without such
prior written consent will be null and void. Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of, and be enforceable by, the parties and their respective successors and assigns. 

21.    Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being
enforced by any rule or Law, or public policy, (a) such term or other provision will be fully separable, (b) this Agreement will be construed and enforced as if such invalid, illegal or unenforceable provision had never comprised a part
hereof, and (c) all other conditions and provisions of this Agreement will nevertheless remain in full force and effect so long as either the economic or legal substance of the transactions contemplated hereby is not affected in any manner
materially adverse to any party or such party waives its rights under this Section 21 with respect thereto. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the
parties hereto will negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner to the end that the Transactions are fulfilled to the extent possible. 

22.    Waiver of Jury Trial. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW,
ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY SUIT, ACTION OR OTHER PROCEEDING ARISING OUT OF THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT
OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH PARTY WOULD NOT, IN THE EVENT OF ANY ACTION, SUIT OR PROCEEDING, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO
HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVER AND CERTIFICATIONS IN THIS SECTION 22. 

23.    Counterparts. This Agreement may be executed in two or more counterparts, each of which will be deemed an
original, but all of which together will constitute one and the same the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000,
e.g., www.docusign.com) or other transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

24.    IRREVOCABLE PROXY. At all times prior to the Termination Date, (a) Shareholder hereby grants to the
Company (and any designee of the Company) a proxy (and appoints the Company or any such designee of the Company as its attorney-in-fact) to appear, cause to be counted,
vote, and to exercise all voting and consent rights of 

 
Shareholder with respect to, the Covered Shares (including, without limitation, the power to execute and deliver written consents) in accordance with, and solely with respect to, Subsection
1(a)(i) at any meeting of shareholders of the Company (whether annual, special or otherwise and whether or not an adjourned or postponed meeting) at which any of the transactions, actions or proposals contemplated by Subsection 1(a)(i)
are or will be considered and in every written consent in lieu of such meeting and (b) such proxy and appointment shall (i) be irrevocable in accordance with the provisions of Bermuda law, (ii) be coupled with an interest, and
(iii) survive the dissolution, bankruptcy or other incapacity of Shareholder; provided, that Shareholder’s grant of the proxy contemplated by this Section 24 shall be effective if, and only if, Shareholder has not
delivered to the Company at least five (5) Business Days prior to the meeting at which any of the matters described in Subsection 1(a)(i) are to be considered, or within five (5) Business Days after any request for a written consent
in lieu of such meeting addressing any of the matters described in Subsection 1(a)(i), a duly executed proxy card directing that all of the Covered Shares of Shareholder be voted in accordance with Subsection 1(a)(i); provided,
further, that any grant of such proxy shall not grant the Company (or any designee of the Company) the right, and Shareholder shall retain the authority, to vote on all other matters, including those matters contemplated by Subsection
1(a)(ii). Shareholder hereby represents that any proxies heretofore given in respect of any of the Covered Shares, if any, are revocable, and hereby revokes all such proxies, and that Shareholder agrees not to grant any subsequent proxies with
respect to any Covered Shares at any time prior to the Termination Date, except to comply with its obligations under Section 1. Shareholder hereby affirms that the irrevocable proxy set forth in this
Section 24, if it becomes effective, is given in connection with the execution of the Merger Agreement, and that such irrevocable proxy is given to secure the performance of the duties of Shareholder under this Agreement.

 25.    Affiliates. Shareholder hereby covenants and agrees that it will cause each of its Affiliates (other
than the Company and the Company Subsidiaries) to comply with this Agreement as if each such Affiliate was itself a party to this Agreement. 

[The remainder of this page is intentionally left blank; signature page follows.] 

 IN WITNESS WHEREOF, the Company and Shareholder have caused to be executed or
executed this Voting and Support Agreement as of the date first written above. 
  

			
	SUMITOVANT BIOPHARMA LTD.
		
	By:	 	/s/ Marianne L. Romeo

 
			
	Name:	 	Marianne L. Romeo

 
			
	Title:	 	Head, Global Transactions & Risk Management

 Signature Page to Voting and Support Agreement 

 IN WITNESS WHEREOF, the Company and Shareholder have caused to be executed or
executed this Voting and Support Agreement as of the date first written above. 
  

			
	 UROVANT SCIENCES LTD.

		
	By:	 	/s/ James Robinson
	Name:	 	James Robinson
	Title:	 	Principal Executive Director

 Signature Page to Voting and Support Agreement 

 SCHEDULE A 

Shareholder owns 22,963,263 Common Shares.EX-4.1

 Exhibit 4.1 

TRANSLATION FROM FRENCH INTO ENGLISH (solely for convenience of English speaking users) 

CONSTELLIUM SE 
 A European
company with share capital of 2,799,253.44 euros 
 Registered Office: Washington Plaza, 40-44 rue
Washington, 75008 Paris 
 Paris Trade and Companies Register n° 831 763 743 

 
  

ARTICLES OF ASSOCIATION 
 (as of
August 3, 2020) 
  

 TITLE I 

FORM, NAME, OBJECT, REGISTERED OFFICE, AND DURATION OF THE COMPANY 

ARTICLE 1 – FORM 
 The company shall be a
European company. 
 Created on May 14, 2010 in the form of a “besloten vennootschap met beperkte aansprakelijkheid” (B.V.) and
transformed into “naamloze vennootschap” (N.V.) on May 21, 2013, it continues to exist among the owners of the shares composing its capital, after transformation into a European company pursuant to a general meeting dated
June 27, 2019 and then transfer of its registered office to France pursuant to a general meeting dated November 25, 2019. 
 It is governed by all
applicable laws and regulations, as well as these Articles of Association. 
 ARTICLE 2 – COMPANY NAME 

The company name is: 
 CONSTELLIUM SE 

In all deeds and documents issued by the company and intended for third parties, the name shall always be immediately preceded or followed by the words:
“société européenne” or the initials “SE” and the amount of share capital. 
 ARTICLE 3 – COMPANY OBJECT

 The object of the company, directly or indirectly, in any form, in France and in all countries, is: 

 

	•	 	 to incorporate, to participate in, to finance, to collaborate with, to manage, to supervise businesses, companies
and other enterprises and provide advice and other services; 

  

	•	 	 to acquire, use and/or assign industrial and intellectual property rights and real property;

  

	•	 	 to finance and/or acquire companies and any businesses; 

 

	•	 	 to borrow, to lend and to raise funds, including through the issue of bonds, debt instruments or other securities
or evidence of indebtedness as well as to enter into agreements in connection with the aforementioned activities; 

  

	•	 	 to invest funds; 

  

	•	 	 to provide guarantees and security for debts of legal persons or of other companies with which the Company is
affiliated in a Group or for the debts of third parties; 

  

	•	 	 to undertake all that which is connected to the foregoing or in furtherance thereof, all of the above being
understood in the broadest sense of the words. 

 ARTICLE 4 – REGISTERED OFFICE 

The company’s registered office and central administration are located at: Washington Plaza, 40-44 rue Washington,
75008 Paris, France. 

  
 2 

 The registered office may be transferred to any other location within the French territory, either by
decision of the ordinary general meeting or by decision of the Board of Directors, subject to such decision being ratified by the next ordinary general meeting. 

If a transfer is approved by the Board of Directors, the latter is authorised to amend the Articles of Association and to carry out the resulting publicity
and filing formalities, provided the transfer is submitted for the ratification mentioned hereinabove. 
 The Board of Directors may establish offices,
agencies, or branches wherever it deems useful, and may also remove them. 
 ARTICLE 5 – DURATION 

The company has a duration of ninety-nine (99) years as from its registration with the Paris Trade and Companies Register, except in cases of early
dissolution or extension as approved by the extraordinary general meeting. 
 TITLE II 

CAPITAL AND SHARES 
 ARTICLE 6
– CAPITAL 
 The capital amounts to two million, seven hundred and ninety-nine thousand, two hundred fifty-three euros and forty-four euro cents
(2.799.253,44 euros). It shall be divided, as from August 3, 2020, into one hundred and thirty-nine million, nine hundred and sixty-two thousand, six hundred and
seventy-two (139.962.672) ordinary shares, each with a nominal value of two euro cents (0.02), fully paid-up and all of the same category. 

ARTICLE 7 – FORM OF SHARES, SHAREHOLDING PROCEDURES 

Shares shall be either registered (“au nominatif”) or bearer (“au porteur”) shares, at the shareholder’s discretion, in
accordance with Article L. 228-1 of the French Commercial Code. 
 Shares of the Company will be registered either
on a register (the “U.S. Register”) maintained in the United States of America by a registrar , or on accounts maintained by the Company (or its agent) or by authorized intermediaries in accordance with Article L. 211-3 of the French Monetary and Financial code (such accounts being collectively referred to as the “French Register”), at the shareholder’s discretion. 

Shares registered on the U.S. Register will either be in the name of Cede & co, acting on behalf of The Depository Trust Company
(“DTC”), or in the name of holders who want to be directly recorded on the U.S. Register. The shares must be held through a participant in the system managed by DTC and registered on the U.S. Register in the name of Cede &
co to be eligible for direct trading on the New York Stock Exchange. Shares registered on the U.S. Register will be in “au porteur” form; they shall be registered in France in the name of a single intermediary in the form of a
collective account for the account of all owners of these shares, in accordance with Article L. 228-1, 7th subparagraph of the French Commercial Code. 

  
 3 

 Shares registered on the French Register may be in “au nominatif” form or in “au
porteur” form, at the shareholder’s discretion, it being specified that these shares may not be traded in this form on the NYSE. 
 On the
effective date of the transfer of the registered office in France, all shares comprising the company’s capital shall be entered in the U.S. Register. Any shareholder seeking to transfer its shares from one register to another will have to give
proper instructions, at its own cost, to its broker or the Company, as the case may be. 
 ARTICLE 8 – TRANSFERS 

Any transfer of shares shall be made pursuant to law and to these Articles of Association. Shares shall be transmitted by transfer between accounts, according
to the procedures defined by the laws and regulations in force. 
 Shares shall be freely transferable. 

ARTICLE 9 – THRESHOLD CROSSING 
 Any natural
person or legal entity acting alone or in concert, who comes to own, directly or indirectly, a number of shares equal to or greater than 5%, 10%, 15%, 20%, 25%, 30%, 33 1/3%, 50%, 66 2/3% or 90% of the total number of shares or voting rights must,
within five (5) trading days after the shareholding threshold is crossed, notify the company, by certified letter with acknowledgement of receipt, of the total number of shares or voting rights that it owns alone, directly or indirectly, or in
concert. 
 Moreover, it shall also inform the company, in its threshold notification letter, (i) of the number of securities held giving deferred
rights to the shares to be issued and the corresponding voting rights, and (ii) of the number of shares already issued or the voting rights it may acquire by virtue of agreements or financial instruments mentioned in Article L. 211-1 of the French Monetary and Financial Code. 
 The same obligations apply if the participation in capital or voting
rights falls below one of the thresholds stipulated hereinabove. 
 Moreover, any person or entity who holds a number of shares equal to or greater than
10%, 15%, 20% or 25% of the total number of shares or voting rights in the company shall, within five (5) trading days after the shareholding threshold is crossed, inform the company of the objectives it intends to pursue over the six
(6) months to come. 
 Following a period of six (6) months, any person or entity who continues to hold a number of shares or voting rights equal
to or greater than the fractions mentioned hereinabove, shall renew its statement of intent, in compliance with the aforementioned terms, for each new period of six (6) months. 

This statement shall specify whether the person or entity is acting alone or in concert, if it plans to discontinue or continue its purchases, to acquire or
not the control of the company, to request its appointment or that of one or several persons as director. 

  
 4 

 The company reserves the right to share with the public and shareholders either the objectives that it has
been notified of, or the relevant person’s failure to comply with the aforementioned obligation. 
 For the application of the preceding subparagraphs,
the shares or voting rights listed in paragraphs 1 to 8 of Article L. 233-9 I of the French Commercial Code shall be considered equivalent to the shares or voting rights held by a person or an entity. 

Neither Cede & Co, acting on behalf of DTC, DTC, nor the intermediary acting as “intermédiaire inscrit” per subparagraph
seven of Article L. 228-1 of the French Commercial Code are required to make the statements covered in this article, for all of the shares for which Cede & Co, DTC and such intermediary, respectively,
are registered in such capacity in the books. 
 ARTICLE 10 – MANDATORY PUBLIC OFFER 

Any natural or legal persons acting alone or in concert within the meaning of Article L. 233-10 of the French
Commercial Code, who comes into possession, otherwise than following a voluntary takeover bid, directly or indirectly, of more than 30% of the equity securities or voting rights of the company, shall file a draft takeover bid on all the capital and
securities granting access to the capital or voting rights, and on terms that comply with applicable U.S. Securities law, rules of the U.S. Securities and Exchange Commission (SEC) and NYSE rules. 

The same requirement applies to natural or legal persons, acting alone or in concert, who directly or indirectly own a number between 30% and half the total
number of equity securities or voting rights of the company and who, in less than twelve consecutive months, increase the holding, in capital or voting rights, of at least 1% of the securities or voting rights of the company. 

When a draft offer is submitted, the price proposed must be at least equal to the highest price paid by the offeror, acting alone or in concert within the
meaning of Article L. 233-10 of the French Commercial Code, over a period of twelve (12) months preceding the event giving rise to the obligation to submit the draft offer. 

In the event of a clear change in the characteristics of the company, if the market for its securities so justifies or in the absence of a transaction by the
offeror, acting alone or in concert, over the company’s shares during the twelve-month period mentioned in the first paragraph, the price will be fixed by an expert appointed in accordance with Article 1592 of the French Civil Code and
determined according to the objective evaluation criteria usually used, the characteristics of the company and the market of its securities, it being specified that the expert will be required to take into account, in its assessment, the criteria
identified by the French Commission des Opérations de Bourse, the French Autorité des Marchés Financiers (“AMF”) and the French courts. 

The obligation to file a draft public offer does not apply if the person or persons concerned justify to the company the fulfilment of one of the conditions
listed in Articles 234-7 and 234-9 of the AMF’s Règlement Général. In the event of disagreement between the parties, an expert will be
appointed, at the request of the most diligent party, by the president of the commercial court, ruling in the form of interim relief, for the purpose of determining whether or not it is necessary to file a draft public offer, it being specified that
the expert will be required to apply the relevant provisions of the AMF’s Règlement Général as well as the criteria issued by the French Conseil des marchés financiers, the AMF and the French courts.

  
 5 

 Neither Cede & Co, acting on behalf of DTC, DTC, nor the intermediary acting as
“intermédiaire inscrit” per subparagraph 7 of Article L. 228-1 of the French Commercial Code are subject to the requirements covered in this article, for all of the shares for which
Cede & Co, DTC and such intermediary, respectively, are registered in such capacity in the books. 
 ARTICLE 11 – RIGHTS AND OBLIGATIONS
ATTACHED TO THE SHARES 
 The rights and obligations attached to the share follow the share, in any hand it passes, and the transfer includes all
dividends accrued, unpaid, and accruing, and, as applicable, the share of reserves and provisions. 
 Share ownership entails, ipso facto, the
holder’s approval of these Articles of Association as well as of the decisions of the general meetings. 
 The voting right attached to the
company’s shares shall be proportional to the percentage of the capital they represent, and each of the company’s shares shall carry one vote. 

Each share entitles the holder, in the ownership of the company assets, profit-sharing, and liquidation surplus, to a percentage proportional to the number of
existing shares, taking into account, as the case may be, the amortised and non-amortised capital, paid-up or unpaid capital, the nominal amount of the shares and the
rights of the different categories of shares. 
 Whenever it is necessary to own more than one share to exercise any right, the single shares or shares in
fewer numbers than required shall confer no rights on their holders against the company, and in such cases the shareholders shall be personally responsible for pooling the required number of shares. 

TITLE III 

COMPANY ADMINISTRATION 

ARTICLE 12 – BOARD OF DIRECTORS 
 1.
Composition 
 The company shall be directed by a Board composed of natural or legal persons between three and eighteen in number, appointed by the
general meeting. In the event of a merger, this number may be increased under the conditions provided by law. 
 Any legal person shall, upon its
appointment, assign a natural person as permanent representative to the Board of Directors. The permanent representative’s term of office shall be the same as that of the legal person he or she is representing. If the legal person removes its
permanent representative, it shall immediately provide a replacement. The same provisions apply in the event of the permanent representative’s death or resignation. 

The general meeting may decide that the Board of Directors shall be renewed annually on a rotating basis, such that this rotation involves a given fraction of
the number of directors. 

  
 6 

 The directors’ term of office is three (3) years renewable. By way of exception,
(a) the general meeting may choose a director for a shorter term so that the renewal of the directors’ terms of office may be spread out over time, (b) the directors in office immediately before the day of registration of the Company
in the registre du commerce et des sociétés of Paris shall remain in office thereafter, for a duration equal to their remaining term of office before such registration. 

A director’s term of office ends at the close of the ordinary general meeting called to approve the financial statements for the past financial year and
held in the year during which the term of office of said director expires. 
 Directors may be reappointed at any time. They may be removed at any time by a
decision of the general meeting. 
 In the event of a vacancy through the death or resignation of one or more directorships, the Board of Directors may make
temporary appointments between two general meetings. The director appointed to replace another director whose term of office has not expired remains in office only for as long as the remaining term of his or her predecessor’s office. 

A company employee may be appointed as a director. His or her employment contract must correspond to an actual position. In such cases he or she does not lose
the benefit of his or her contract of employment. 
 The number of directors bound to the company by a contract of employment may not exceed one-third (1/3) of the directors in office. 
 The number of directors who are more than seventy-five (75) years of
age shall not exceed one-third (1/3) of the directors in office. If this limit is exceeded during the terms of office, the oldest director shall automatically be considered to have resigned at the close of the
next general meeting. 
 2. Chair – Bureau of the Board of Directors 

The Board of Directors elects a Chairman from among its members who must be a natural person. The Board of Directors sets his or her term office, which cannot
exceed that of his or her directorship, and may remove him or her at any time. The Board sets his or her compensation. 
 The Chairman organises and directs
the tasks of the Board, which he or she then reports to the general meeting. He or she oversees the proper functioning of the various bodies of the company and, in particular, ensures that the directors are able to fulfil their mission. 

The Board Chairman may not be more than seventy-five (75) years of age. If the Chairman reaches that age during his or her term, he or she shall
automatically be considered to have resigned. However, his or her term of office shall be extended until the next meeting of the Board of Directors during which his or her successor shall be appointed. Subject to this provision, the Board Chairman
may be re-elected at any time. 
 Moreover, the Board, if it sees fit, appoints a vice-chairman from among its
members, whose term of office it sets within the limit of that of his or her directorship.  
 The Board appoints a secretary, who may be
chosen from outside the directors and shareholders. 

  
 7 

 ARTICLE 13 – MEETING OF THE BOARD OF DIRECTORS 

The Board of Directors meets as often as required by the company’s interests, at the registered office or at the location indicated in the convening
notice, and at least every three (3) months. 
 Directors shall be convened to Board meetings by the Chairman. Convocation may be made through
any written means. 
 The Chairman must convene the Board of Directors within seven (7) days following a reasoned request made in this sense by the
Chief Executive Officer, if the offices of Chairman and Chief Executive Officer are separate, or at least one-third (1/3) of the members of the Board of Directors. If this request goes unanswered, the
requesters may themselves convene the meeting, stating the agenda. 
 Moreover, the directors representing at least
one-third (1/3) of the Board members may validly convene the meeting if the Board of Directors has not met for more than two (2) months. In this case, they must state the meeting’s agenda. 

The Board meets either at the company’s registered office or in any other location in France or outside France. 

An attendance record shall be kept, and the minutes drawn up after each meeting. 

Meetings of the Board of Directors shall be chaired by the Board Chairman. In the event of the Chairman’s absence or prevention, the Board of Directors
shall entrust the Chairman’s duties to the vice-chairman. In the event of the absence or prevention of these latter, the Board shall appoint one of its members to chair each meeting; if there is a tied vote for this appointment, the meeting
shall be chaired by the eldest candidate. 
 For the Board’s deliberations to be valid, more than half of the Board members must be present or
represented. 
 The Board of Directors’ decisions shall be taken by a majority vote; if the votes are tied, the Chairman’s vote shall be decisive.

 Decisions that are within the competence of the Board of Directors may also be taken by written consultation of the directors under the conditions and
within the limits set down by French Law. These decisions currently include those provided for by the French Commercial Code in Article L. 225-24 (co-optation of
directors), the last paragraph of Article L. 225-35 (authorization of security interests, endorsements and guarantees), the second paragraph of Article L. 225-36
(amendment of the articles of association to comply with legal and regulatory provisions) and I of Article L. 225-103 (convening of shareholders’ meetings) and the decisions to transfer the registered
office within the same department. 
 In addition to the relevant provisions of these Articles of Association, the Board of Directors may adopt rules of
procedure in order to organize its decision-making process and working method, including the rules in case of a conflict of interest. These rules of procedure may stipulate, specifically, that the directors attending the Board meeting via
videoconference and telecommunications methods shall be considered to be in attendance, in accordance with regulations in force. 

  
 8 

 Each director receives the information required to perform his or her duties and, by virtue of his or her
office, may obtain any and all documentation he or she deems useful. 
 Any director may assign the power, even by letter, fax, or electronic mail, to
another director to represent him or her in a Board meeting, but each director may only have one proxy during a meeting. 
 Copies or extracts of the
deliberations of the Board of Directors shall be validly certified by the Chairman of the Board of Directors, the Chief Executive Officer, the Deputy Chief Executive Officers, the director temporarily delegated to the duties of the chairman, or a
proxy authorised for that purpose. 
 ARTICLE 14 – POWERS AND DUTIES OF THE BOARD OF DIRECTORS 

The Board of Directors sets the guidelines for the company’s activity and oversees their implementation, in accordance with its corporate interest, taking
into consideration the social and environmental impact of its activity. Subject to the powers expressly assigned by law to the shareholders’ meetings and within the limit of the corporate purpose, it hears any issue relevant to the
company’s smooth operation and, by means of its deliberations, settles the matters of concern to it. 
 In its relations with third parties, the
company shall be bound even by the decisions of the Board of Directors that do not come under the corporate purpose, unless the company can prove that the third party knew that the decision exceeded that purpose or that it could not have been
unaware of this in light of the circumstances; publication of the Articles of Association alone does not constitute sufficient proof. 
 The Board of
Directors proceeds with the controls and checks that it deems advisable. 
 Moreover, the Board of Directors exercises the special powers conferred on it by
law. 
 The Board of Directors may appoint, from within, one or more special committees, of which it sets the composition and powers and which carry out
their activity under its responsibility. Each committee shall report on its missions at the next meeting of the Board of Directors. 
 Directors, non-voting members, and any other person called to attend meetings of the Board of Directors are bound not to disclose, as applicable, even after the end of their duties, the information they have on the company and
the disclosure of which could compromise the company’s interests, except for cases in which such disclosure is required or allowed by law or in the public interest. 

ARTICLE 15 – GENERAL MANAGEMENT 
 The
company’s executive management shall be assumed by a natural person appointed by the Board of Directors and given the title of Chief Executive Officer (directeur général). 

If the company’s executive management is assumed by the Chairman (président), the laws, regulations, and statutes pertaining to the Chief
Executive Officer shall be applicable to him or her. He or she shall take the title of Chairman and Chief Executive Officer (président-directeur général). 

  
 9 

 The Chief Executive Officer shall be vested with the broadest powers to act in all circumstances in the
company’s name. He or she shall exercise his or her powers within the scope of the corporate purpose and subject to those that the law expressly assigns to shareholders’ meetings and the Board of Directors. 

He or she shall represent the company in its relations with third parties. The company shall be bound even by the actions of the Chief Executive Officer that
do not belong to the corporate purpose, unless it can prove that the third party knew that the decision exceeded that purpose or that it could not have been unaware of this in light of the circumstances; publication of the Articles of Association
alone does not constitute sufficient proof. 
 The Chief Executive Officer shall not be more than seventy (70) years of age. If the Chief Executive
Officer reaches that age limit, he or she shall be considered to have resigned. However, his or her term of office shall be extended until the next meeting of the Board of Directors during which the new Chief Executive Officer is appointed. 

The Board of Directors may remove the Chief Executive Officer at any time. If the removal is approved without due cause, it may give rise to damages, unless
the Chief Executive Officer is taking office as the Chairman of the Board of Directors. 
 By a simple resolution passed by a majority vote of the directors
present or represented, the Board of Directors shall choose whether the general management of the company is to be assumed by the Chairman of the Board or by another natural person. 

Shareholders and third parties shall be informed of this choice in accordance with the laws and regulations. 

The Board of Directors’ choice thus made shall remain in force until an opposing decision by the Board or, at the Board’s discretion, throughout the
Chief Executive Officer’s term of office. 
 If the company’s general management is assumed by the Chairman of the Board of Directors, the
provisions applicable to the Chief Executive Officer shall be applicable to him or her. 
 On a proposal by the Chief Executive Officer, the Board of
Directors may appoint one or more natural persons to assist the Chief Executive Officer as Deputy Chief Executive Officer (directeur général délégué). 

In agreement with the Chief Executive Officer, the Board of Directors shall set the scope and duration of the powers conferred on the Deputy Chief Executive
Officers. The Board of Directors shall set their compensation. If a Deputy Chief Executive Officer is a director, his or her duties cannot outlast his or her directorship. 

With regard to third parties, Deputy Chief Executive Officers have the same powers as the Chief Executive Officer; Deputy Chief Executive Officers have the
power to litigate. 
 The number of Deputy Chief Executive Officers may not exceed five. 

The Deputy Chief Executive Officer(s) shall be removable at any time by the Board of Directors, as proposed by the Chief Executive Officer. If the removal is
approved without due cause, it may give rise to damages. 

  
 10 

 A Deputy Chief Executive Officer may not be more than seventy (70) years of age. If a Deputy Chief
Executive Officer in office reaches that age limit, he or she shall automatically be considered to have resigned. However, his or her term of office shall be extended until the next meeting of the Board of Directors during which a new Deputy Chief
Executive Officer could potentially be appointed. 
 If the Chief Executive Officer ceases to perform or is prevented from performing his or her duties, the
Deputy Chief Executive Officer(s) shall retain all duties and powers until the appointment of the new Chief Executive Officer, unless decided otherwise by the Board of Directors. 

ARTICLE 16 – NON-VOTING MEMBERS 

The Board of Directors may appoint one or more non-voting members (censeurs) from among the shareholders,
natural or legal persons, or elsewhere, but they shall not be more than two (2) in number. 
 The non-voting
members’ term of office shall be set by the Board of Directors, not to exceed three (3) years. The duties of a non-voting member shall end at the close of the ordinary general meeting called to
approve the financial statements for the past year and held in the year during which the term of office of said non-voting member expires. 

Non-voting members may be re-elected at any time. The Board of Directors may
put an end to their term of office at any time. 
 In the event of the death, resignation, or severance of a
non-voting member for any other reason, the Board of Directors may replace him or her for the remainder of his or her term of office. 

Non-voting members shall be called upon to attend meetings of the Board of Directors as observers and may be consulted
by the latter or by the Chairman and take part in the deliberations with a consultative voice only; however their absence cannot affect the validity of the deliberations. They shall be convened to Board meetings under the same conditions as
directors. 
 Non-voting members shall not be remunerated for their duties. However, the Board of Directors may
authorise the reimbursement of the expenses that the non-voting members incur in the company’s interest. 

ARTICLE 17 – INDEMNIFICATION OF DIRECTORS 

The members and former members of the Board of Directors shall be reimbursed for: 
  

	 	(a)	 reasonable cost of conducting a defense against claims, including claims by the company (other than such claims
for which such members or former members of the Board have been declared responsible for by a final court decision), based on acts or failures to act in the exercise of their duties or any other duties currently or previously performed by them at
the company’s request; and 

  

	 	(b)	 any damages payable by them as a result of an act or failure to act in the exercise of their duties or any
other duties currently or previously performed by them at the company’s request. 

  
 11 

 There shall be no entitlement to indemnity: 

 

	 	(a)	 if and to the extent the laws of France would not permit such indemnification; 

 

	 	(b)	 if and to the extent a competent court has established in a final and conclusive decision that the act or
failure to act of the current or former member of the Board may be characterized as willful (faute intentionnelle), intentionally reckless (faute lourde) or falling outside the exercise of its duties (faute détachable);
or 

  

	 	(c)	 if and to the extent the costs, damages or fines payable by the current or former member of the Board are
covered by any liability insurance and the insurer has paid out the costs, damages or fines. 

 Except if the claim is instituted by the
company itself, the relevant current or former member of the Board of Directors shall follow the company’s instructions relating to the manner of his or her defense and consult with the company in advance about the manner of such defense. The
person concerned shall not: (i) acknowledge any personal liability, (ii) waive any defense, or (iii) agree on a settlement, without the company’s prior written consent. The company may take out liability insurance for the benefit
of current or former members of the Board. 
 ARTICLE 18 – RELATED-PARTY AGREEMENTS 

Pursuant to subparagraph 6 of Article L. 229-7 of the French Commercial Code, Articles
L. 225-38 to L. 225-42 of the said Commercial Code are applicable to agreements entered into by the company. 

TITLE IV 

STATUTORY AUDITORS 
 ARTICLE
19 – STATUTORY AUDITORS 
 The company is audited, per the conditions set by law, by one or more statutory auditors meeting the legal conditions
of eligibility. When the legal conditions are met, the company shall appoint at least two statutory auditors. 
 Each statutory auditor shall be appointed
by the ordinary general meeting. 
 If the ordinary general meeting fails to elect a statutory auditor, any shareholder may petition the court to appoint
one, with the Chairman of the Board of Directors duly summoned. The term of office of the court-appointed statutory auditors shall end when the ordinary general shareholders’ meeting has duly appointed the statutory auditor(s). 

TITLE V 

GENERAL MEETINGS 
 ARTICLE 20

 1. Convocation 
 General meetings shall be
convened and held per the conditions and deadlines set forth by the laws and regulations. 

  
 12 

 Meetings shall be held at the registered office or at any other location specified in the convocation. 

2. Entitlement 
 The right to attend general meetings
shall be documented by the book entry of shares in the name of the shareholder or of the intermediary registered on his or her behalf in the company registers in accordance with the deadlines and conditions set forth by law. 

Shareholders who do not attend the meeting in person may choose one of the following options: 

 

	 	•	 	 be represented by the intermediary registered on their behalf; or 

 

	 	•	 	 assign a proxy to another shareholder, to their spouse, or to the partner with whom they have entered into a
civil union (pacte civil de solidarité); or 

  

	 	•	 	 vote by mail; or 

  

	 	•	 	 send a proxy to the company without indicating an assignment, in accordance with the conditions set forth by the
laws and regulations in force. 

 3. Videoconference voting 

Under the conditions set forth by applicable laws and regulations, the Board of Directors may arrange for shareholders to attend and vote by videoconference or
other means of telecommunications that allow for a person’s identification. If the Board of Directors decides to exercise this option for a given meeting, the Board of Directors’ decision is recorded in the meeting notice and/or
convocation. 
 Shareholders attending meetings by videoconference or any of the other means of telecommunications mentioned hereinabove, at the Board of
Directors’ discretion, shall be considered present for the calculation of quorum and majority. 
 4. Committee – Attendance sheet –
minutes 
 Meetings shall be presided over by the Chairman of the Board of Directors or, in his or her absence, by the Chief Executive Officer, by a
Deputy Chief Executive Officer if he or she is a director, or by a director specially appointed for that purpose by the Board. Failing that, the meeting shall elect its own Chairman. 

The committee shall include a Chairman and two scrutineers. The scrutineers’ duties shall be performed by the two members of the meeting who have the
highest number of votes, if they are present and accept these duties. 
 The committee shall appoint a secretary, who need not be a shareholder. 

At each meeting, an attendance sheet shall be kept, with the powers assigned to authorised agents appended to it as well as any absentee ballots, and minutes
shall be taken of the meeting. 
 This attendance sheet may be regularised by the general meeting committee following the company’s acceptance of the
information transmitted by the registrar of the U.S. Register on the disposals made, before the second (2nd) business day preceding the meeting at zero hour, Paris time, as applicable, by
shareholders who have already cast their vote before that date. Indeed, 

  
 13 

 
the company is obligated to invalidate or amend votes cast by shareholders who have thus disposed of their shares, pursuant to Articles R. 225-85 and R. 225-86 of the French Commercial Code. Consequently, in view of the transmission deadlines for this information, the attendance sheet prepared at the general meeting shall be a draft document until it is regularised.
The outcome of voting on the resolutions shall be final after the information thus transmitted is taken into account. 
 Copies or extracts of the meeting
minutes shall be validly certified by the Chairman of the Board of Directors, by a director performing the duties of Chief Executive Officer, or by the meeting secretary. 

5. Quorum and majority 
 Shareholders’ decisions
shall be made at the general meeting. 
 Only the extraordinary general meeting shall be authorised to amend any or all provisions of the Articles of
Association. 
 The ordinary general meeting shall make all other decisions falling within the competence of a general meeting. 

Special meetings shall be attended by holders of a given category of shares, assuming that such is created, to decide on any amendment to the rights in
respect of shares of that category. 
 The ordinary general meeting held on the date set by the first convening notice validly deliberates where the
shareholders present, represented or having voted by correspondence hold at least one-fifth (1/5) of the voting shares. If this quorum is not reached, a second meeting is convened with an agenda identical to
the first meeting; no quorum is required for such second meeting. 
 The extraordinary general meeting held on the date set by the first convening notice
validly deliberates where the shareholders present, represented or having voted by correspondence hold at least a quarter (1/4) of the voting shares. If this quorum is not reached, a second meeting is convened with an agenda identical to the first
meeting. If the quorum at the second meeting is not reached, the second meeting can be postponed to a date no later than two months after the date on which the second meeting was convened. The quorum for such second or postponed meeting, as the case
may be, to be validly held is 1/5 of the voting shares. 
 Special meetings held on the date set by the first convening notice may validly deliberate where
the shareholders present, represented or having voted by correspondence hold at least one third (1/3), on first notice, and, failing which, 1/5 for the meeting held on the date set by the second convening notice or in the case of postponement of the
second meeting. 
 The ordinary general meeting’s decisions shall be made by a majority of votes validly cast. 

Decisions of the extraordinary general meetings and special meetings shall be made by a two-thirds (2/3) majority of votes validly cast. 

Votes cast shall not include those attached to shares for which the shareholder has not taken part in voting or has abstained or has returned a blank or
invalid vote. 

  
 14 

 TITLE VI 

COMPANY RESULTS 
 ARTICLE 21
– FINANCIAL YEAR 
 Each financial year shall last one calendar year, beginning on 1 January and ending on 31 December. 

ARTICLE 22 – PROFITS - LEGAL RESERVE 
 A
mandatory deduction of five percent (5%) of the profit for the financial year, minus any prior losses, shall be allocated to creating a reserve fund known as the “legal reserve.” This deduction shall cease to be mandatory once the amount
of the legal reserve reaches one-tenth (1/10) of the capital. 
 Distributable profit shall comprise profit for the
financial year, minus any prior losses and the deduction stipulated in the preceding subparagraph, plus accumulated profit. 
 ARTICLE 23 –
DIVIDENDS 
 If the financial statements for the year, as approved by the general meeting, show a distributable profit, the general meeting shall
decide to enter it in one or more reserve accounts of which it governs the allocation or use, to carry it forward, or to distribute it as dividends. 

After recording the existence of reserves available to it, the general meeting may decide to distribute funds deducted from those reserves. In this case, the
decision shall expressly indicate the reserve accounts from which these deductions are made. However, dividends shall first be deducted from the distributable profit for the financial year. 

The procedures for issuing payment of dividends shall be set by the general meeting or by the Board of Directors, as appropriate. 

Distributions payable in cash shall be approved in euro and paid (i) in euro for all holders of shares held on the French Register and (ii) in U.S.
dollars (USD) for all holders of shares entered in the U.S. Register. 
 For the purposes of paying the dividend in dollars, the general meeting or, as
appropriate, the Board of Directors shall set the reference date to be applied for the EUR/USD conversion price. 
 Dividend payment shall be issued no
later than nine (9) months after the close of the financial year. 
 The general meeting approving the financial statements for the year may grant each
shareholder, for some or all of the dividend being distributed, the choice of cash or shares in payment of the dividend. 
 Likewise, each shareholder may
be granted an interim distribution, and for some or all of said interim distribution, the choice of cash or shares in payment of the interim distribution. 

  
 15 

 The offer of payment in shares, the price, and the conditions for issuing the shares, as well as the request
for payment in shares and the conditions for the capital increase, shall be governed by the laws and regulations in force. 
 The Board of Directors may
decide to carry out interim distributions under the conditions set out by the laws and regulations in force. 
 TITLE VII 

DISSOLUTION · LIQUIDATION 

ARTICLE 24 – EARLY DISSOLUTION 
 The
extraordinary general meeting may decide on the company’s early dissolution at any point in time. 
 ARTICLE 25 – LOSS OF ONE-HALF OF CAPITAL 
 If, due to losses recorded in the accounting documents, the shareholders’ equity falls
below one-half of the registered capital, the Board of Directors shall, within four months from approval of the financial statements showing such a loss, convene the extraordinary general meeting for the
purpose of deciding whether the early dissolution of the company is justified. 
 If the decision is not made to dissolve, the capital shall, no later than
the closure of the second financial year following the one during which the losses were recorded, and subject to the laws relating to the minimum capital of sociétés anonymes, be reduced by an amount equal to or greater than any
losses that could not be charged against the reserves, if, during that period, the equity capital has not been restored to a value equal to or greater than one-half of the capital. 

If the general meeting is not held, or if that meeting fails to validly deliberate, any interested party may petition the court for the company’s
dissolution. 
 ARTICLE 26 – EFFECTS OF DISSOLUTION 

The company shall be in liquidation from the moment it is dissolved for any reason whatsoever. Its legal personality shall persist for the purposes of this
liquidation until the closure thereof. 
 Throughout the liquidation period, the general meeting shall retain the same powers as it had during the
company’s existence. 
 Shares shall remain tradeable until the closure of the liquidation. 

The company’s dissolution shall only have effect with respect to third parties from the date on which said dissolution is published in the trade and
corporate register. 
 ARTICLE 27 – APPOINTMENT OF LIQUIDATORS – POWERS 

At the expiration of the company’s duration or in the event of early dissolution, the general meeting shall govern the mode of liquidation and appoint one
or more liquidators, whose powers it shall set and who shall perform their duties in compliance with the law. 

  
 16 

 The appointment of liquidators puts an end to the duties of the directors, the Chairman, the Chief Executive
Officer, and the Deputy Chief Executive Officers. 
 TITLE VIII 

NOTIFICATIONS 
 ARTICLE 28

 All notifications provided under these Articles of Association shall be made by certified letter with acknowledgement of receipt or by
extrajudicial act. Simultaneously, a duplicate of the notification shall be sent to its recipient by regular mail. 
 TITLE IX

 DISPUTES 

ARTICLE 29 
 Any disputes that may arise during the
life of the company or its liquidation, either among shareholders or between the company and the shareholders, as to the construal or execution of these Articles of Association or, generally, regarding company matters, shall fall within the
jurisdiction of the competent courts of the location of the registered office. 
 As such, in case of a dispute, each shareholder must elect domicile under
the jurisdiction of the competent court of the location of the registered office, and all summons and notices shall be lawfully issued to this domicile. 

If no domicile is elected, the summons and notices shall be validly made to the Office of the Public Prosecutor (Procureur de la
République) of the regional court (Tribunal de Grande Instance) of the location of the registered office. 

  
 17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}]]